

Pantep Angchaisuksiri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/290499/publications.pdf>

Version: 2024-02-01

47
papers

2,281
citations

218677

26
h-index

223800

46
g-index

50
all docs

50
docs citations

50
times ranked

3299
citing authors

#	ARTICLE	IF	CITATIONS
1	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Advances, 2022, 6, 664-671.	5.2	53
2	Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Advances, 2022, 6, 3422-3432.	5.2	22
3	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Advances, 2022, 6, 4915-4923.	5.2	42
4	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Advances, 2022, 6, 4975-4982.	5.2	21
5	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. TH Open, 2021, 05, e24-e34.	1.4	16
6	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 326-341.	2.3	23
7	American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Advances, 2021, 5, 872-888.	5.2	310
8	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. Thrombosis Research, 2021, 201, 63-72.	1.7	14
9	The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. Thrombosis Research, 2021, 203, 155-162.	1.7	9
10	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Advances, 2021, 5, 3951-3959.	5.2	49
11	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. Journal of Thrombosis and Haemostasis, 2021, 19, 3031-3043.	3.8	14
12	Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. Journal of Thrombosis and Haemostasis, 2021, , .	3.8	8
13	TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021063.	1.3	1
14	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. JAMA Network Open, 2020, 3, e2022886.	5.9	28
15	Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Thrombosis Journal, 2020, 18, 34.	2.1	76
16	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. Journal of Thrombosis and Thrombolysis, 2020, 50, 267-277.	2.1	54
17	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thrombosis Research, 2020, 191, 103-112.	1.7	22
18	International Society on Thrombosis and Haemostasis core curriculum project: Core competencies in laboratory thrombosis and hemostasis. Journal of Thrombosis and Haemostasis, 2019, 17, 1848-1859.	3.8	8

#	ARTICLE	IF	CITATIONS
19	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1675-1685.	3.4	34
20	Oral anticoagulant-associated bleeding requiring hospitalization in Thai patients: Incidences, risk factors, and outcomes. <i>Thrombosis Research</i> , 2019, 183, 33-35.	1.7	2
21	Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. <i>Blood</i> , 2019, 134, 1973-1982.	1.4	103
22	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.	3.8	30
23	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.	3.4	28
24	Treatment outcome and prognostic factors in PCNSL. <i>Diagnostic Pathology</i> , 2019, 14, 56.	2.0	24
25	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019, 213, 35-46.	2.7	45
26	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	3.7	44
27	Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2019, 8, 3.	5.0	17
28	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	3.4	76
29	Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data. <i>Haemophilia</i> , 2019, 25, 60-66.	2.1	32
30	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	2.2	28
31	Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. <i>International Angiology</i> , 2017, 36, 1-20.	0.9	108
32	Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE). <i>Thrombosis and Haemostasis</i> , 2016, 116, 1172-1179.	3.4	46
33	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. <i>Lancet Haematology</i> , 2016, 3, e379-e387.	4.6	136
34	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. <i>International Journal of Cardiology</i> , 2016, 223, 543-547.	1.7	71
35	Cancer-associated thrombosis in Asia. <i>Thrombosis Journal</i> , 2016, 14, 26.	2.1	16
36	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	2.5	118

#	ARTICLE	IF	CITATIONS
37	Thrombosis: A Major Contributor to Global Disease Burden. Seminars in Thrombosis and Hemostasis, 2014, 40, 724-735.	2.7	103
38	Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients. Thrombosis Research, 2014, 134, 957-962.	1.7	4
39	Coagulopathy in malaria. Thrombosis Research, 2014, 133, 5-9.	1.7	53
40	Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood, 2014, 124, 3880-3886.	1.4	163
41	Tropical hemostasis/thrombosis. Thrombosis Research, 2013, 132, 635-636.	1.7	0
42	Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients. Blood, 2013, 122, 211-211.	1.4	15
43	Establishment of Carrier Detection and Prenatal Diagnosis Service for Hemophilia in a Developing Country: Experience From International Hemophilia Training Center-Bangkok.. Blood, 2012, 120, 3162-3162.	1.4	0
44	Venous thromboembolism in Asia – an unrecognised and under-treated problem?. Thrombosis and Haemostasis, 2011, 106, 585-590.	3.4	60
45	Risk factors of venous thromboembolism in Thai patients. International Journal of Hematology, 2007, 86, 397-402.	1.6	50
46	Hemostatic and thrombotic markers in patients with hemoglobin E/ β^0 -thalassemia disease. American Journal of Hematology, 2007, 82, 1001-1004.	4.1	44
47	Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. American Journal of Hematology, 2000, 65, 119-122.	4.1	54